Researchers at the University of Zagreb, who have studied the peptide BPC-157 since the 1990s, summarized their rat studies across the digestive tract in a peer-reviewed review, including injuries caused by those painkillers.
The review reports that in the group's rat experiments, BPC-157 counteracted lesions caused by NSAIDs and alcohol from the esophagus to the intestine, and also helped heal surgical joins and fistulas in the gut. The peptide was first derived from a protein found in human gastric juice.
Nearly all of this work comes from the same Zagreb group, and a review written by the researchers who ran the original experiments is not the same as independent replication. No trial has tested BPC-157 for NSAID protection in people, and it is not an approved drug, so the rat findings describe a mechanism worth studying further, not a therapy.
Read the original study
Sikiric et al., Current Pharmaceutical Design, 2011 · doi.org/10.2174/138161211796196954
A mechanism in rats, not yet a therapy.
Source
- Sikiric, P., Seiwerth, S., Rucman, R., Turkovic, B., Rokotov, D. S., Brcic, L., Sever, M., Klicek, R., Radic, B., Drmic, D., Ilic, S., Kolenc, D., Vrcic, H., & Sebecic, B. (2011). Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design, 17(16), 1612–32. https://doi.org/10.2174/138161211796196954